v3.26.1
CONSOLIDATED BALANCE SHEETS - USD ($)
$ in Thousands
Mar. 31, 2026
Dec. 31, 2025
ASSETS    
Cash and cash equivalents $ 13,060 $ 15,956
Prepaid and other current assets 960 1,747
Total current assets 14,020 17,703
Property and equipment, net 16 18
Other assets 23 23
Total assets 14,059 17,744
Liabilities    
Accounts payable 510 1,019
Accrued liabilities 2,805 2,052
Total current liabilities 3,315 3,071
Other long-term liabilities 72 72
Total liabilities 3,387 3,143
Contingencies (Note 13)
Stockholders' Equity    
Common stock, $0.001 par value, authorized 500,000,000 shares; issued 9,108,029 and 8,834,613 shares at March 31, 2026 and December 31, 2025, respectively; and outstanding, 9,107,291 and 8,833,875 shares at March 31, 2026 and December 31, 2025, respectively 9 9
Additional paid-in capital 580,787 580,243
Treasury stock, at cost; 738 shares at March 31, 2026 and December 31, 2025 (708) (708)
Accumulated deficit (569,141) (564,652)
Accumulated other comprehensive loss (21) (37)
Total Lisata Therapeutics, Inc. stockholders' equity 10,926 14,855
Non-controlling interests (254) (254)
Total equity 10,672 14,601
Total liabilities, non-controlling interests and stockholders' equity $ 14,059 $ 17,744